Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Intratus over its Eyelid drug delivery platform. San Clemente, Calif.-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive Eyelid drug delivery platform for treating presbyopia, according to a news release. Financial terms were not disclosed. […]
Intratus
Glaukos licenses eye drug-delivery tech from Intratus
Glaukos (NYSE:GKOS) said today that it inked a licensing deal with Intratus for that company’s transdermal drug delivery platform for treating eye conditions. San Diego-based Intratus developed cream-based drug formulations that are applied to the outer eyelid to treat conditions such as dry eye disease, glaucoma, allergy, blepharitis and conjunctivitis. The deal gives San Clemente, Calif.-based […]